187 related articles for article (PubMed ID: 17287627)
1. A functional clotting assay to monitor the hirudin dosage.
Zakir RM; Hoffman W; Bhatt BA; Spillert CR
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):119-23. PubMed ID: 17287627
[TBL] [Abstract][Full Text] [Related]
2. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.
Sucker C; Zotz RB; Görlinger K; Hartmann M
Acta Anaesthesiol Scand; 2008 Mar; 52(3):358-62. PubMed ID: 18205897
[TBL] [Abstract][Full Text] [Related]
3. Clinical monitoring of hirudin and direct thrombin inhibitors.
Nowak G
Semin Thromb Hemost; 2001 Oct; 27(5):537-41. PubMed ID: 11668425
[TBL] [Abstract][Full Text] [Related]
4. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.
Choi TS; Khan AI; Greilich PE; Kroll MH
Am J Clin Pathol; 2006 Feb; 125(2):290-5. PubMed ID: 16393689
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies on various assays for the laboratory evaluation of r-hirudin.
Walenga JM; Hoppensteadt D; Koza M; Pifarre R; Fareed J
Semin Thromb Hemost; 1991 Apr; 17(2):103-12. PubMed ID: 1771408
[TBL] [Abstract][Full Text] [Related]
6. Methods for the monitoring of direct thrombin inhibitors.
Hafner G; Roser M; Nauck M
Semin Thromb Hemost; 2002 Oct; 28(5):425-30. PubMed ID: 12420237
[TBL] [Abstract][Full Text] [Related]
7. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
8. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
Moser M; Ruef J; Peter K; Kohler B; Gulba DC; Paterna N; Nordt T; Kübler W; Bode C
J Thromb Thrombolysis; 2001 Oct; 12(2):165-9. PubMed ID: 11729368
[TBL] [Abstract][Full Text] [Related]
9. Monitoring fondaparinux with the Sonoclot.
Nilsson CU; Engström M
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):619-22. PubMed ID: 17890948
[TBL] [Abstract][Full Text] [Related]
10. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications.
Harder S; Parisius J; Picard-Willems B
Thromb Res; 2008; 123(2):396-403. PubMed ID: 18571698
[TBL] [Abstract][Full Text] [Related]
11. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.
Tripodi A; Chantarangkul V; Arbini AA; Moia M; Mannucci PM
Thromb Haemost; 1993 Aug; 70(2):286-8. PubMed ID: 8236136
[TBL] [Abstract][Full Text] [Related]
12. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices.
Ganter MT; Hofer CK
Anesth Analg; 2008 May; 106(5):1366-75. PubMed ID: 18420846
[TBL] [Abstract][Full Text] [Related]
13. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.
Demir M; Iqbal O; Untch B; Hoppensteadt DA; Gaikwad BS; Fareed J
Clin Appl Thromb Hemost; 2001 Jan; 7(1):38-43. PubMed ID: 11190903
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors.
Taketomi T; Szlam F; Vinten-Johansen J; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2007 Dec; 18(8):761-7. PubMed ID: 17982317
[TBL] [Abstract][Full Text] [Related]
15. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.
Nowak G
Pathophysiol Haemost Thromb; 2003 Jul-2004 Aug; 33(4):173-83. PubMed ID: 15583446
[TBL] [Abstract][Full Text] [Related]
16. Measurement of patients' bivalirudin plasma levels by a thrombelastograph ecarin clotting time assay: a comparison to a standard activated clotting time.
Carroll RC; Chavez JJ; Simmons JW; Snider CC; Wortham DC; Bresee SJ; Cohen E
Anesth Analg; 2006 May; 102(5):1316-9. PubMed ID: 16632802
[TBL] [Abstract][Full Text] [Related]
17. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography.
Sørensen B; Ingerslev J
Haemophilia; 2005 Nov; 11 Suppl 1():1-6. PubMed ID: 16219042
[TBL] [Abstract][Full Text] [Related]
18. Facts and artefacts of coagulation assays for factor Xa inhibitors.
Haas S
Thromb Haemost; 2010 Apr; 103(4):686-8. PubMed ID: 20174751
[No Abstract] [Full Text] [Related]
19. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of factor IIa inhibitors on the endogenous thrombin potential.
Beilfuss A; Grandoch M; Wenzel F; Hohlfeld T; Schrör K; Weber AA
Ther Drug Monit; 2008 Dec; 30(6):740-3. PubMed ID: 18824953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
